Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers

Bibliography

• Cornely OA, Maertens J, Winston DJ, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R, Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403
   PubMed Web of Science ®Google Scholar
• Krieter P, Flannery B, Musick T, Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Richards W, Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53
   PubMed Web of Science ®Google Scholar
• SP Europe. Noxafil 40 mg/ml oral suspension [Summary of Product Characteristics]. 2008
   Google Scholar
• Merck & Co, Inc. ZOCOR® (simvastatin) tablets. 2008
   Google Scholar
• Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41
   PubMed Web of Science ®Google Scholar
• Schering Corp. NOXAFIL® (posaconazole) oral suspension. 2008
   Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Natl Canc Inst Web Site 2006;1-72
   Google Scholar
• Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro inhibition analysis of 8 cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A. Antimicrob Agents Chemother 2009;53:541-51
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. VFEND® I.V (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension. 2007
   Google Scholar
• Ishigam M, Uchiyama M, Kondo T, Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 2001;18:622-31
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Kunze KL, Allen KE, Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61
   PubMed Web of Science ®Google Scholar
• Shaukat A, Benekli M, Vladutiu GD, Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032-5
   PubMed Web of Science ®Google Scholar
• Kahri J, Valkonen M, Backlund T, Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005;60:905-7
   PubMed Web of Science ®Google Scholar
• Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008;100:444-6
   PubMed Web of Science ®Google Scholar
• Findling O, Meier N, Sellner J, Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole. Neurology 2008;71:e34-7
   Google Scholar
• Rowan C, Brinker AD, Nourjah P, Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18:301-9
   PubMed Web of Science ®Google Scholar
• Maxa JL, Melton LB, Ogu CC, Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 2002;36:820-3
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009;31:286-98
   PubMed Web of Science ®Google Scholar
• Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465-70
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anaesth Analg 1996;82:511-16
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Leino K, Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362-70
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Ubeaud-Sequier G, Engel P, Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009;10:395-409
   PubMed Web of Science ®Google Scholar
• Chen KY, Ko SC, Hsueh PR, Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 2001;120:177-84
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997;43:7-35
   PubMedGoogle Scholar
• Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7
   PubMed Web of Science ®Google Scholar
• Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011;7:49-62
   PubMed Web of Science ®Google Scholar
• Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429-45
   PubMedGoogle Scholar
• Templeton IE, Thummel KE, Kharasch ED, Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008;83:77-85
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-68
   PubMed Web of Science ®Google Scholar
• Meyer Zu Schwabedissen HE, Bottcher K, Chaudhry A, Liver X receptor alpha and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 2010;52:1797-807
   PubMed Web of Science ®Google Scholar